<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240127060820N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-21</date_registration>
      <primary_sponsor>University of Kerbala</primary_sponsor>
      <public_title>Comparing the Effect of Using Lidocaine Spray and ShotBlocker on Pain Level During Intramuscular Injection: A Clinical Trial</public_title>
      <acronym>RCT</acronym>
      <scientific_title>Comparing the Effect of Using Lidocaine Spray and ShotBlocker on Pain Level During Intramuscular Injection: A Randomized Control Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75385</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: In order to maintain a transparent and scientifically based randomization process, stratified randomization will be used in assigning participants (Patients receiving intramuscular injections {diclofenac sodium} who are admitted to the emergency department) to intervention (shotblocker and lidocaine spray) and control groups. This method ensures that each participant has an equal chance of being assigned to any group. The process will involve a simple randomization procedure wherein participants will select a color from a sealed envelope containing three colors: blue, yellow, and green. Each color corresponds to a group (blue for the ShotBlocker group, yellow for the lidocaine spray group, and green for the control group), and participants will be allocated randomly among these three groups, Blinding description: the single-blind technique, was employed as the researcher needs to know how the subjects will be treated. Therefore, the study was done whereas the participants were unaware of the interventional group. With the use of this blinding technique, the study results are well shielded from the subject knowledge of the treatment assignment . There have been (153) patients in the sample. Both the intervention groups and the control group obtained an equal number of these subjects .</study_design>
      <phase>N/A</phase>
      <hc_freetext>Patients receiving intramuscular injections {diclofenac sodium} who are admitted to the emergency department.</hc_freetext>
      <i_freetext>Intervention group: The study included adult patients who were chosen based on the aforementioned criteria. The study was carried out in the emergency departments with patients who had been prescribed diclofenac sodium by their physicians. To reassure the participants, the researcher explained the study's aims, duration, and technique in terms of information confidentiality. Following that, the oral and written consents of the patients who will participate in the sample were obtained, as they were randomly divided into three groups (Total 153). This method ensures that each participant has an equal chance of being assigned to any group. The process will involve a simple randomization procedure wherein participants will select a color from a sealed envelope containing three colors: blue, yellow, and green. Each color corresponds to a group (blue for the ShotBlocker group, yellow for the lidocaine spray group, and green for the control group), and participants will be allocated randomly among these three groups .The injection procedure and the randomization method for selecting one of the groups are discussed with participations. The researcher introduced the patients to the Visual Analog Scale (VAS) pain intensity scale before administering the injection, placing a check in front of the number denoting the degree of the pain..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be the results of Patients receiving intramuscular injections {diclofenac sodium} who are admitted to the emergency department for both  intervention  and control groups,

When:
God Willing, once the article is published, the data will be
available after 6 months of publication. If the article will
be published in a subscribed journal, the data will be
available after one year because of the policy of the
subscribed journals.

To whom:
with academic nurses and any researcher who is
interested in the data

Conditions:
The data could be used after getting permission via
email. Also, users need to acknowledge the owner.

Where to obtain:
Users can ask for the data and permission via email.
Hameed Muslim is the corresponding author. He will
contact whoever he requests the information from. His
email is  hameed.muslim@s.uokerbala.edu.iq  Hameed Muslim
works at the Imam Al-Sadiq General Hospital .
The address is Al-Hussein neighborhood  district, Karbala, Iraq.
What processes are involved for a request to access
data/document

How to obtain:
Users can ask for the data and permission via email.
Hameed Muslim is the corresponding author. He will
contact whoever he requests the information from. His
email is  hameed.muslim@s.uokerbala.edu.iq

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hameed Muslim Hashem</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Hussein neighborhood</address>
        <city>Karbala</city>
        <country1>Iraq</country1>
        <zip>56001</zip>
        <telephone>+964 781 864 0782</telephone>
        <email>hameed.muslim@s.uokerbala.edu.iq</email>
        <affiliation>University of Kerbala</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hameed Muslim Hashem</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Hussein neighborhood</address>
        <city>Karbala</city>
        <country1>Iraq</country1>
        <zip>56001</zip>
        <telephone>+964 781 864 0782</telephone>
        <email>hameed.muslim@s.uokerbala.edu.iq</email>
        <affiliation>University of Kerbala</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iraq</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adult participants between the ages of 18 – 60 years old; did not receive analgesics/sedatives during the past 24 hours; voluntary participated in the study; patient did not have fibrosis, wound, infection and tenderness in the injection site: patients who entered the Emergency Department and were prescribed analgesics by the physicians: have no problems communicating and are fully conscious: patient not have diseases Gastric Ulcers and Asthma.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who refused to participate in the study; individuals with communication difficulties or unconsciousness, those with fibrosis, wounds, or infections at the injection site, individuals involved in Road Traffic Accidents (RTA), stab wounds, or bleeding injuries. Patients receiving medication (such as antibiotics or analgesics) intravenously or intramuscularly, pregnant women, and individuals experiencing side effects of Diclofenac Sodium like gastric ulcers and asthma were also excluded from the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The study included adult patients who were chosen based on the aforementioned criteria. The study was carried out in the emergency departments with patients who had been prescribed diclofenac sodium by their physicians. To reassure the participants, the researcher explained the study's aims, duration, and technique in terms of information confidentiality. Following that, the oral and written consents of the patients who will participate in the sample were obtained, as they were randomly divided into three groups (Total 153). This method ensures that each participant has an equal chance of being assigned to any group. The process will involve a simple randomization procedure wherein participants will select a color from a sealed envelope containing three colors: blue, yellow, and green. Each color corresponds to a group (blue for the ShotBlocker group, yellow for the lidocaine spray group, and green for the control group), and participants will be allocated randomly among these three groups .The injection procedure and the randomization method for selecting one of the groups are discussed with participations. The researcher introduced the patients to the Visual Analog Scale (VAS) pain intensity scale before administering the injection, placing a check in front of the number denoting the degree of the pain.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome variable is the level of pain during intramuscular injection  that can be changed based on using shotblocker and lidocaine spray. Timepoint: immediate after intervention (intramuscular injection ) using visual analog scale and after three weeks to  measurement of the primary outcome. Method of measurement: measurement pain level after intramuscular injection by using visual analog scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The author of the trial is the funding source</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-19</approval_date>
        <contact_name>Ethics committee in College of Nursing at University of Karbala</contact_name>
        <contact_address>Al Iskan Street, Al Hussein District Karbala,  Iraq</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
